ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.3
  1. ホーム
  2. /化合物

ミトキサントロン

Mitoxantrone

HCID 4212
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
65271-80-9
標準SMILES
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
分子式
C22H28N4O6
平均分子量
444.5 g/mol
単同位体質量
444.20088462

概要

Mitoxantrone is a dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8. It has a role as an analgesic and an antineoplastic agent.

名称と識別子

優先名称
Mitoxantrone
IUPAC
1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
現地名
ミトキサントロン
英語名
Mitoxantrone
分子式
C22H28N4O6
分子量
444.48

名称と別名

mitoxantrone65271-80-9MitozantroneMitoxanthroneDHAQMitoxantronMitoxantronaMitoxantronumMisostolNSC-279836NSC 279836BZ114NVM5P
名称をさらに表示
5,8-ジヒドロキシ-1,4-ビス[[2-[(2-ヒドロキシエチル)アミノ]エチル]アミノ]-9,10-アントラキノン1,4-ジヒドロキシ-5,8-ビス[2-(2-ヒドロキシエチルアミノ)エチルアミノ]-9,10-アントラキノン1,4-ジヒドロキシ-5,8-ビス[[2-[(2-ヒドロキシエチル)アミノ]エチル]アミノ]-9,10-アントラキノン1,4-ジヒドロキシ-5,8-ビス[2-(2-ヒドロキシエチルアミノ)エチルアミノ]-9,10-アントラセンジオンミトキサントロン1,4-ジヒドロキシ-5,8-ビス[[2-[(2-ヒドロキシエチル)アミノ]エチル]アミノ]-9,10-アントラセンジオン1,4-ジヒドロキシ-5,8-ビス[2-[(2-ヒドロキシエチル)アミノ]エチルアミノ]-9,10-アントラキノン1,4-ビス[[2-[(2-ヒドロキシエチル)アミノ]エチル]アミノ]-5,8-ジヒドロキシ-9,10-アントラキノン1,4-ジヒドロキシ-5,8-ビス({2-[(2-ヒドロキシエチル)アミノ]エチル}アミノ)-9,10-ジヒドロアントラセン-9,10-ジオン5,8-ジヒドロキシ-1,4-ビス(5-ヒドロキシ-3-アザペンタン-1-イルアミノ)アントラセン-9,10-ジオン1,4-ビス[2-(2-ヒドロキシエチルアミノ)エチルアミノ]-5,8-ジヒドロキシ-9,10-アントラキノンitoxantronedihydroxyanthraquinoneNSC-27983MitoxantroneBasePharmasubstanceEP4
NSC2798361,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedioneDTXSID40469471,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONECHEBI:50729L01DB07Ralenova

物性

構造計算による物性

XLogP
1
極性表面積
163 Ų
水素結合供与体数
8
水素結合受容体数
10
回転可能結合数
12
重原子数
32
形式電荷
0
複雑度
571

実験および物理化学的性質

Drugs · 2 件

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

LogP · 2 件

-3.1

0.07

Solubility7.34e-01 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Antineoplastic Agents
Physical DescriptionLiquid
Collision Cross Section198.57 Ų [M+Na]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
170 · 170-1740C
沸点
554.47 °C · 554.47°C (rough estimate)
比重(密度)
1.3049 · 1.3049 (rough estimate)
屈折率
1.65 · 1.6500 (estimate)
貯蔵温度
2 · Keep in dark place,Sealed in dry,2-8°C
溶解性
DMSO(少々)、メタノール(少々)、水(少々)
酸解離定数(Pka)
5.99 · pKa 5.99 (Uncertain);8.13 (Uncertain)

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Warning

H351 (100%): Suspected of causing cancer [Warning Carcinogenicity]

P203, P273, P280, P318, P391, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationHazard Traits - Carcinogenicity
Hazard Classes and CategoriesCarc. 2 (100%)

毒性情報

Health EffectsCardiomyopathy is a particularly concerning effect as it is irreversible. [Wikipedia]
Hepatotoxicity · 1 件

Chemotherapy with mitoxantrone alone is associated with serum enzyme elevations in up to 40% of patients, but these elevations are generally mild-to-moderate in severity, transient and not accompanied by symptoms or jaundice. Higher rates of liver enzyme elevations have been reported with combination chemotherapeutic regimens that include mitoxantrone. In high doses, mitoxantrone has been associated with a high rate of jaundice, but the degree of hyperbilirubinemia has been mild, transient and not associated with significant serum enzyme elevations or evidence of hepatitis. Rare instances of acute liver injury have been reported in patients taking mitoxantrone, including a single case of drug-rash with eosinophilia and systemic symptoms (DRESS). The latency to onset was 8 weeks and the pattern of serum enzyme elevations was cholestatic and later mixed. Immunoallergic features were prominent and appeared to respond to corticosteroid therapy. Other drugs were being taken and the association with mitoxantrone was not definite (Case 1). Thus, idiosyncratic and clinically apparent liver injury from mitoxantrone may occur but is quite rare.

化学と産業

薬理情報

ATC Code · 3 件

L01DB07

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding78%
PharmacodynamicsMitoxantrone has been shown in vitro to inhibit B cell, T cell, and macrophage proliferation and impair antigen presentation, as well as the secretion of interferon gamma, TNFa, and IL-2.
Mechanism of Action · 1 件

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Biological Half-Life75 hours
Metabolism/Metabolites · 2 件

Hepatic

Hepatic Half Life: 75 hours

FDA Pharmacological Classification · 6 件

BZ114NVM5P

MITOXANTRONE

Established Pharmacologic Class [EPC] - Topoisomerase Inhibitor

Mechanisms of Action [MoA] - Topoisomerase Inhibitors

Mitoxantrone is a Topoisomerase Inhibitor. The mechanism of action of mitoxantrone is as a Topoisomerase Inhibitor.

MITOXANTRONE

MeSH Pharmacological Classification · 3 件

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.

関連反応

22 件
反応記録を作成
HRID 65397 の反応式
HRID 65397反応物として
HRID 65398 の反応式
HRID 65398反応物として
HRID 370432 の反応式
HRID 370432生成物として
HRID 370573 の反応式
HRID 370573反応物として
HRID 370574 の反応式
HRID 370574反応物として
HRID 477419 の反応式
HRID 477419生成物として
HRID 620290 の反応式
HRID 620290反応物として
HRID 647783 の反応式
HRID 647783反応物として
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
65271-80-9
PubChem CID
4212
DTXSID
DTXSID4046947
ChEMBL
CHEMBL58
ChEBI
CHEBI:50729
UNII
BZ114NVM5P
EC Number
833-758-3
Nikkaji
J19.969I、J710.751J
外見
個体
色
ダークブルーからブラック
InChI
InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2
InChIKey
KKZJGLLVHKMTCM-UHFFFAOYSA-N
SMILES
C1(O)=C2C(C(=O)C3=C(C2=O)C(NCCNCCO)=CC=C3NCCNCCO)=C(O)C=C1
CAS データベース
65271 · 65271-80-9(CAS DataBase Reference)

化学的性質

化学的特性Dark Blue Crystalline Solid

Exposure RoutesIntravenous injection. Poorly absorbed following oral administration.
Toxicity Summary · 1 件

Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks and strand breaks. Mitoxantrone also interferes with ribonucleic acid (RNA) and is a potent inhibitor of topoisomerase II, an enzyme responsible for uncoiling and repairing damaged DNA. It has a cytocidal effect on both proliferating and nonproliferating cultured human cells, suggesting lack of cell cycle phase specificity.

Signs and SymptomsSevere leukopenia with infection.
Carcinogen Classification · 6 件

Mitoxantrone

Group 2B: Possibly carcinogenic to humans

Volume 76: (2000) Some Antiviral and Antineoplastic Drugs, and Other Pharmaceutical Agents

2000

1999

2B, possibly carcinogenic to humans. (L135)

Drug Induced Liver Injury · 5 件

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

mitoxantrone

DILI Positive

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

安全データ

wgk
3
rtecs
CB5748500
hs_code
2922.50.2500
risk_code
46-61-26/27/28
hazard_code
T,T+
safety_code
53-36/37/39-45-22
Absorption, Distribution and Excretion · 3 件

Poorly absorbed following oral administration

1000 L/m2

21.3 L/hr/m2 [Elderly patients with breast cancer receiving IV administration of 15-90 mg/m2]

Cellular LocationsCytoplasm

用途と製造

Uses · 2 件

Use (kg) in USA (2002): 1

For the treatment of secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. Mitoxantrone is an Anthracenedione (not an anthracycline) antineoplastic agent.

応用分野

使用Mitoxantrone is a DNA intercalating drug. Mitoxantrone inhibits DNA synthesis. Mitoxantrone is used as an anti-cancer agent.

上流・下流製品情報

上流原料

Dihydro-1,4,5,8-tetrahydroxyanthraquinone2-(2-アミノエチルアミノ)エタノールクロラニルN,N,N',N'-テトラメチルエチレンジアミン2,3-ジヒドロ-1,4,5,8-テトラヒドロキシ-9,10-アントラセンジオン